CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC)

Yunhong Tian†, Jianlin Wu†, Cristian Chagas³, Yichao Du⁴, Huan Lyu¹, Yunhong He¹, Shouliang Qi⁵, Yong Peng¹* and Jiani Hu³*

Abstract

Background: Accurate and early prognosis of disease is essential to clinical decision making, particularly in diseases, such as HCC, that are typically diagnosed at a late stage in the course of disease and therefore carry a poor prognosis. CDCA5 is a cell cycle regulatory protein that has shown prognostic value in several cancers.

Methods: We retrospectively evaluated 178 patients with HCC treated with curative liver resection between September 2009 and September 2012 at Nanchong Central Hospital in Nanchong, Sichuan Province, China. Patients were screened for their CDCA5 expression levels and assigned to either the high or low expression group. Patient demographics, comorbidities, clinicopathologic data, such as tumor microvascular invasion status and size, and long-term outcomes were compared between the two groups. The effect of CDCA5 on the proliferation of liver cancer cells was analyzed using in vitro and in vivo assays.

Results: The present study found that increased CDCA5 expression was associated with increased tumor diameter and microvascular invasion in HCC. It was also found that CDCA5 overexpression may be associated with liver cancer cells. Additionally, this study confirmed that CDCA5 expression was increased in HCC tissue versus normal liver tissue, that CDCA5 expression was associated with decreased survival and that CDCA5 knockdown using shRNA led to cell cycle arrest in the G2/M phase.

Conclusions: These findings suggest that CDCA5 expression is associated with poor prognosis in patients with hepatocellular carcinoma.

Keywords: CDCA5, Prognosis, Hepatocellular carcinoma
Recent studies have correlated the expression of CDCA5 with tumorigenesis and tissue invasion in several cancers, including oral squamous cell cancer, non-small cell lung cancer, urothelial cell carcinoma, and gastric cancer [7–9].

The objective of this study was to confirm the prognostic value of CDCA5 expression levels in HCC and to shed light on tumor characteristics associated with CDCA5 expression. This was accomplished by (1) examining the effects of CDCA5 expression on microvascular invasion and tumor diameter in HCC using resected specimens from our patient population, (2) determining differences in CDCA5 expression levels between HCC, normal hepatic, and peri-tumoral hepatic tissues, (3) confirming the effects of CDCA5 expression on the postoperative survival rate of HCC patients by performing a retrospective analysis of our patient population, and (4) confirming the effects of CDCA5 expression on viability, proliferation, and apoptosis in hepatoma cell lines using knockdown and gene amplification in vitro and in a mouse model.

Methods
Clinical data
A retrospective analysis of the clinical data from 178 patients who underwent curative liver resection for HCC between September 2009 and September 2012 was performed. All procedures were performed by the department of hepatobiliary surgery at Nanchong Central Hospital in Nanchong, Sichuan Province, China. Patients’ age, gender, preoperative Child-Pugh score, serum AFP value, platelet count, HBV-DNA status, MELD score, and antiviral treatment use were collected. Postoperative pathological details, including liver cirrhosis, tumor diameter, number of tumors, minimum distance from the tumor margin, anatomical liver resection, intraoperative blood transfusion, tumor capsule information, microvascular invasion, Edmondson-Steiner grade, and postoperative complications, were also recorded and obtained. This study was approved by the Ethics Committee of the Second Clinical Medical College of North Sichuan Medical College.

Materials
An anti-CDCA5 monoclonal antibody was purchased from Abcam. The lentiviruses pSICOR and pCDH-CMV-MCS-EF1-Puro, HepG2 cell lines, DNA gel recovery kits, and LATaq were purchased from Huaxianke. Endotoxin plasmid extraction kits were purchased from Huaxianke. RibonucleaseA (RNaseA) was purchased from TaKaRa. The DH5α strain was obtained from existing laboratory stocks.

Cell culture
SMMC-7721, HepG2, and Huh-7 cells were cultured in DMEM containing 10% fetal bovine serum and 1% penicillin at 37 °C in a 5% CO2 incubator. The cells were then digested in 0.25% trypsin and subcultured.

Experimental animals
Twelve SPF grade BALB/C-nu/nu nude mice, 4 to 6 weeks old and weighing 18–20 g, were purchased from Beijing Huafu Kang Biotechnology Co., Ltd. They were raised in an SPF animal room.

Immunohistochemical staining
The specific steps of anti-CDCA5 monoclonal antibody immunohistochemical staining were performed according to the kit instructions. The main staining procedures were as follows: paraffin section dewaxing, hydration, 3% H2O2 incubation to eliminate endogenous peroxidase activity, high pressure antigen retrieval, normal goat serum blocking, primary antibody (CDCA5 monoclonal antibody) incubation overnight at 4 °C, and 3 PBS washes. The secondary antibody (goat anti-rabbit IgG antibody-HRP) was then added. After the incubation, the tissues were rinsed 3 times with PBS. DAB staining, hematoxylin counter staining, alcohol dehydration, transparent xylene incubation, and neutral gum sealing were performed. Prepared samples were observed via microscopy.

Plasmid construction
Total RNA was extracted from human hepatoma tissue and reverse transcribed into cDNA. This cDNA was used as a template to amplify the CDCA5 gene by using primers specific for CDCA5 (CDCA5-F: GCTCTAGATGTCTGGGAGGGCAGAACGC, CDCA5-R: CCGGATCTCTCATTTCAAACCAGGAGATCA). This CDCA5 gene and the plasmid pCDH-CMV-MCS-EF1-Puro were double-digested with Xba I and BamH I, and the CDCA5 gene was subsequently ligated into the plasmid pCDH-CMV-MCS-EF1-Puro using T4 DNA ligase. This construct was then transformed into competent DH5α cells. Positive clones were used to expand the cultures, and the plasmids were extracted using an endoviral plasmid extraction kit. The CDCA5 overexpression plasmid with the correct sequence was named pCDH-CDCA5. Based on the GenBank sequence of CDCA5 (NM_080668.3), 3 shRNA interference sequences were designed using the shRNA design program. In
addition, Xho I and BamH I restriction sites were introduced into the 5’ and 3’ ends of the shRNAs, and the double-stranded DNA oligo containing the interference sequence was synthesized according to this design. The pSICOR vector and the synthesized interference sequence were double-enzyme linearized by T4 DNA. The construct was then ligated into the pSICOR vector by T4 DNA ligase and transformed into competent DH5α cells. The positive clones were picked and expanded. The plasmid was extracted using an endotoxin plasmid extraction kit, and the correctly sequenced CDCA5 interference plasmid was named pSICOR-shCDCA5. Plasmids were sent to Shanghai Huajin Biotechnology Co., Ltd. for sequencing.

**MTT assay**

HepG2 cells were seeded into petridishes and infected with each plasmid. The HepG2 normal cells group, CDCA5 low expression group, and CDCA5 overexpression group logarithmic phase cells were collected, and the cell suspension was distributed into a 96-well plate with 180 μL per well (1~5 × 10⁴ cells/well) in triplicate, and 100 μL culture solution was used as the blank control. The cells were incubated at 37 °C for 12 h, 24 h, 48 h, and 72 h. Then, 20 μL MTT solution (5 mg/ml) was added to each well, and then the cells were cultured for 4 h. Then, 150 μL DMSO solution was added to each well after the supernatant was discarded. The plate was shaken at low speed for 10 min to fully dissolve the crystals. The 490 nm absorbance of each well was measured in an enzyme-linked immunosorbent assay.

**Colony formation**

Cells were trypsinized, washed, diluted 1/10 and seeded into 10 cm dishes after transfection. Cells were grown for 2 weeks, after which colonies were stained with Coomassie blue (0.1% Coomassie blue, 30% methanol, 10% acetic acid) and counted.

**Flow cytometry detection of the cell cycle**

The CDCA5 low expression group cells, CDCA5 overexpression group cells and negative control HepG2 cells were digested with 0.25% trypsin, transferred to flow cytometry tubes, and centrifuged at 1000 rpm for 5 min. Each precipitate was suspended in 300 μl PBS solution containing 10% fetal bovine serum and then transferred into a clean 1.5 ml centrifuge tube. Then, 700 μl anhydrous ethanol was added, and the cells were fixed in a refrigerator at −20 °C for at least 24 h. Flow cytometry was performed to quantify the number of cells in each stage of the cell cycle.

**Tumorigenicity experiment in nude mice**

Six mice were assigned to each group. HepG2 cells with low expression of CDCA5 and the negative control cells were digested with 0.25% trypsin, and the cell numbers were counted. The cell concentration was adjusted to 1 × 10⁷ cells/ml with serum-free medium. A 0.2 ml cell solution was subcutaneously injected into each mouse using both HepG2 cells with low expression of CDCA5 and negative control cells. We observed the survival of the nude mice and the growth of the tumors. All nude mice were sacrificed by cervical dislocation on the 30th day, and the tumors were removed. The average weights of the tumors in each group were calculated.

**Statistical analysis**

Continuous data are shown as the mean ± standard deviation. Comparisons of continuous data were carried out using Student’s t test or the Mann-Whitney U test. Multiple groups of measurement data were compared using one-way ANOVA. Categorical variables were compared using the chi-square test or Fisher’s exact test as appropriate. The Kaplan-Meier method was used to estimate survival probabilities, which were compared using the log-rank test. All statistical tests were two-tailed, and a P value < 0.05 was considered significant. Statistical calculations performed using SPSS software (IBM version 22.0, NY) [10].

**Results**

**Clinical and pathological features of patients**

**Clinical characteristics**

After a review of the inclusion and exclusion criteria, 178 patients were included in the study. The average ages of the patients in the CDCA5 high expression group and the CDCA5 low expression group were 50.70 ± 10.02 and 49.54 ± 9.64 years, respectively. The average follow-up time was 40.2 months. There were no significant differences in clinical features between the two groups in terms of gender, liver function, Child-Pugh score, alpha fetoprotein (AFP) level, platelet (PLT) count, antiviral therapy use, hepatitis B virus DNA (HBV-DNA) status, or Model-End-Stage liver disease (MELD) score (Table 1).

**Pathological features**

Patients with CDCA5 overexpression had larger tumor diameters and a higher incidence of microvascular invasion compared with patients with decreased CDCA5 expression. The odds of microvascular invasion in the high CDCA5 expression group were over twice that in the low expression group. There were no significant differences in the proportion of cirrhotic patients, number of tumors, tumor capsule characteristics, or the degree of differentiation between the two groups (Table 1).

**The expression of CDCA5 in HCC**

We used the median of the semiquantitative CDCA5 expression data from the 178 HCC tissue samples as a
cutoff point for high and low expression of CDCA5. There were 89 patients with high expression of CDCA5 and 89 patients with low expression of CDCA5. Compared to normal liver tissue, HCC tissue exhibited significantly increased expression of CDCA5 \((P < 0.05)\) (Figs. 1, 2).

Survival analysis

**Effect of the CDCA5 expression level on the postoperative survival rate of HCC patients**

The 1-, 3-, and 5-year disease-free survival rates in the CDCA5 overexpression group were 69.7, 46.1, and 32.6%, respectively. The 1-, 3-, and 5-year overall survival rates in the CDCA5 overexpression group were 86.5, 61.5, and 47.8%, respectively. The 1-, 3-, and 5-year disease-free survival rates in the CDCA5 low expression group were 84.3, 64.0, and 44.9%, respectively. The 1-, 3-, and 5-year overall survival rates in the CDCA5 low expression group were 89.9, 76.4, and 64.0%, respectively. The survival rates of the patients in the CDCA5 overexpression group were worse than those of the patients in the CDCA5 low expression group \((P < 0.05)\) (Fig. 3).

**Expression of CDCA5 in HCC cell lines**

We selected the SMMC-7721, HepG2, and Huh-7 HCC cell lines and detected the expression of CDCA5 protein by Western blotting. HepG2 cells had the highest expression of CDCA5 and were selected for the knockdown experiment. SMMC-7721 cells had the lowest expression of CDCA5 and were selected for the overexpression experiments. Plasmids that knocked down and overexpressed CDCA5 were constructed, and Western blotting was used to detect changes in CDCA5 expression after knockdown and overexpression (Fig. 4). Finally, we chose to use the pSicoR-shCDCA5–3 and pCDH-CDCA5 plasmids in the following experiments.

**MTT assay**

The proliferation rates were detected by an MTT assay after CDCA5 knockdown in HepG2 cells and CDCA5 overexpression in SMMC-7721 cells. The growth inhibition rates of the HepG2 cells in the knockdown group

---

**Table 1** The clinical and pathologic characteristics of the included patients

| Variable                                | Patients (178) | CDCA5 overexpression group | Low CDCA5 expression group | Odds Ratio | \(P\) value |
|-----------------------------------------|----------------|----------------------------|----------------------------|------------|-------------|
| Liver cirrhosis, n(%)                   | 128 (71.91)    | 63 (70.79)                 | 65 (73.03)                 | 0.895      | 0.739       |
| Tumor diameter, median (range)          | 5.88 ± 3.83    | 6.67 ± 3.97                | 5.11 ± 2.42                | 0.890      | 0.006       |
| Tumor number, (%)                       |                |                            |                            |            |             |
| 1                                       | 156 (87.64)    | 82 (92.13)                 | 74 (83.15)                 | 0.624      | 0.189       |
| 2                                       | 16  (8.99)     | 5  (5.62)                  | 11  (12.36)                |            |             |
| \(\geq 3\)                              | 6  (3.37)      | 2  (2.25)                  | 4  (4.49)                  |            |             |
| Tumor margin,< 2/+2 cm                   | 45/178         | 22/67                      | 23/66                      | 0.942      | 0.897       |
| Anatomic/nonanatomic liver resection    | 73/105         | 38/51                      | 35/54                      | 1.105      | 0.648       |
| Intraoperative blood transfusion, Yes/No| 27/151         | 15/74                      | 12/77                      | 1.301      | 0.531       |
| Tumor capsule, complete/incomplete      | 88/90          | 39/50                      | 43/46                      | 0.834      | 0.548       |
| Microvascular invasion, present/absent  | 44 / 134       | 28 / 61                    | 16 / 73                    | 2.094      | 0.037       |
| Edmondson-Steiner Grade I / II / III / IV| 33 / 78 / 65 / 2| 12 / 37 / 38 / 2| 21 / 41 / 27 / 0| 0.608 | 0.089 |

---

**Fig. 1** Immunohistochemistry shows CDCA5 expression in normal liver tissue (a) and liver cancer tissue (b). (DAB staining, hematoxylin counterstain, magnification: 400 x)
after transfection with pSicoR-CDCA5–3 were 8.40 ± 2.07%, 14.10 ± 0.53%, 65.97 ± 0.58% and 70.10 ± 1.04% at 12, 24, 48 and 72 h, respectively (P < 0.05). When the transfection time was prolonged, the growth rate of the HepG2 cells in the CDCA5 knockdown group was significantly decreased. The survival rates of the SMMC-7721 cells in the overexpression group were 102.83 ± 1.56%, 116.23 ± 1.01%, 128.93 ± 0.95% and 130.03 ± 0.35% at 12, 24, 48 and 72 h, respectively (P < 0.05). When the transfection time was prolonged, the survival rate of the SMMC-7721 cells in the CDCA5 overexpression group was significantly increased.

**Colony formation assay**

The colony formation rate was 16.49 ± 1.75% in the CDCA5 knockdown group compared to 32.17 ± 3.25% in the negative control group. The quantity of clones formed in the CDCA5 low expression group was less than that of the negative control group (P < 0.05)(Fig. 5.1). The proliferation ability of HepG2 cells was attenuated after CDCA5 knockdown. After CDCA5 overexpression, the colony formation rate was 51.93 ± 3.46%, while it was 34.57 ± 4.86% in the negative control group. The quantity of clones formed in the CDCA5 overexpression group was greater than that of the negative control group (P < 0.05). The proliferation ability of SMMC-7721 cells was increased after CDCA5 overexpression (Fig. 5.2).

**Flow cytometry**

Flow cytometry was used to analyze the cell cycle phases of the HepG2 cells with low CDCA5 expression, SMMC-7721 cells with CDCA5 overexpression, and negative controls. The accumulation of G2 phase cells was significantly increased in the CDCA5 low expression group compared with the negative controls. There were no significant differences between the CDCA5 overexpression group and the negative control group with regard to cell distribution in the cell cycle phases. The results suggested that the inhibition of HepG2 cell growth was associated with arrest in the G2 phase after CDCA5 knockdown (Fig. 6.1, 6.2, Table 2).

Changes in cell cycle profiles of SMMC-7721 cells after the overexpression of CDCA5.

---

**Fig. 2** Immunohistochemistry shows CDCAS expression in tumor tissue and peritumor tissue samples. (DAB staining, hematoxylin counterstain, magnification: 200 x)

**Fig. 3** The survival curves for the CDCAS overexpression group and the low CDCAS expression group.
There were slightly fewer cells in the G2/M phase among the SMMC-7721 cells that overexpressed CDCA5 from pCDH-CDCA5 than among the negative control SMMC-7721 cells. However, these results were statistically insignificant (Fig. 6.3, 6.4, Table 3).

**Tumor formation experiments in nude mice**

In the control group injected with HepG2 cells, tumors were detectable on the fifth day. In contrast, in the CDCA5 low expression group, tumors were detectable on the sixth day. On the 30th day after injection, the

**Fig. 4** CDCA5 protein expression after shRNA interference or overexpression by plasmid liposomes encoding CDCA5. 1. Control group; 2. Negative control group; 3. shCDCA5–1 interference group; 4. shCDCA5–2 interference group; 5. shCDCA5–3 interference group; 6. CDCA5 overexpression group

**Fig. 5** 1 HepG2 cell colony formation assay. 2 SMMC-7721 cell colony formation assay
tumor weights in the control group and the CDCA5 low expression group were 0.89 ± 0.07 and 0.66 ± 0.11 g, respectively. Tumors from the HepG2 group were heavier than those from the low CDCA5 expression group, and the difference between the two groups was statistically significant (P < 0.05) (Fig. 7.1, 7.2).

**Immunohistochemical detection of CDCA5 expression in tumor tissue**

CDCA5 expression was significantly decreased in the tumor tissue from the CDCA5 low expression group compared with that from the HepG2 group (P < 0.05). (Fig. 8).

**Discussion**

HCC is the third leading cause of cancer-related death globally, accounting for over 700,000 deaths per year [2]. The disease carries a high mortality rate because treatments are invasive, frequently requiring liver resection, and patients tend to present with later stage disease as the early stages are asymptomatic. Accurate prognosis is an important step in the management of patients diagnosed with HCC. The main results of this study are as follows: (1) CDCA5 expression is directly correlated with microvascular invasion, (2) CDCA5 expression is directly correlated with tumor diameter, and (3) CDCA5 overexpression is associated with changes in cell cycle parameters as quantified by flow cytometry. In addition, CDCA5 expression was confirmed to be inversely related to disease-free and overall survival in HCC patients. CDCA5 expression was also confirmed to be higher in HCC samples than in normal liver samples. In hepatoma cell lines, CDCA5 expression was confirmed to increase cell viability and proliferation, while CDCA5 inhibition caused decreased rates of proliferation and apoptosis based on colony formation assays, flow cytometry, and nude mouse experiments [11]. These results suggest that CDCA5 is a useful biomarker for prognosis.

The incidence of microvascular invasion was higher in patients with overexpression of CDCA5 (45.90%) than in those with low expression of CDCA5 (21.92%). Although an association between CDCA5 and microvascular

---

**Table 2** The cell cycle distribution of HepG2 cells in the low expression group and control group

| Group                        | G1 (%)  | S (%)   | G2/M (%) |
|------------------------------|---------|---------|----------|
| Control group                | 57.44 ± 1.25 | 29.92 ± 0.22 | 11.73 ± 1.97 |
| Low CDCA5 expression group   | 45.81 ± 3.37 | 27.37 ± 2.78 | 27.53 ± 0.58 |
| P value                      | 0.005   | 0.189   | < 0.001  |

**Table 3** The cell cycle distribution of SMMC-7721 cells in the over expression group and control group

| Groups                        | G1 (%)  | S (%)   | G2/M (%)  |
|-------------------------------|---------|---------|-----------|
| Negative control group        | 59.04 ± 1.76 | 29.38 ± 1.21 | 11.86 ± 1.22 |
| CDCA5 over expression group   | 63.25 ± 2.10 | 27.97 ± 4.05 | 9.55 ± 0.60 |
| P value                       | 0.057   | 0.595   | 0.050     |
invasion in urothelial carcinoma has been shown [11], this is
the first study reporting this relationship in HCC. Previous
studies have found that microvascular invasion is predictive
of survival in patients with HCC, which may explain find-
ings regarding CDCA5 expression and survival [12–14].

This was also the first study demonstrating that
CDCA5 expression was directly correlated with tumor
diameter. The median tumor diameter in the high
CDCA5 expression group was 6.67 ± 3.97 versus 5.11 ±
2.42 in the low CDCA5 expression group (P = 0.006).
Tumor diameter has been shown to have a significant
impact on postoperative survival in HCC patients [13]
and is included in multiple liver cancer staging systems,
such as the TNM staging system and Milan liver trans-
plantation criteria [15, 16]. Tumor size alone, however,
is not sufficient to determine a cancer prognosis. Studies
have shown that the biological characteristics of tumors
and remnant liver function in patients who have under-
gone liver resection were more impactful in terms of
predicting overall survival [17]. Combining other pre-
dictive factors, such as molecular biomarkers and tumor
location, with a tumor diameter index is likely to be a
better approach to determine prognosis.

This is the first study comparing the effects of differ-
et levels of increased CDCA5 expression in
CDCA5-positive HCC cells. These results suggest that
higher levels of CDCA5 expression in HCC may be asso-
ciated with liver cancer progression. This is consistent
with our hypothesis that CDCA5 expression is associ-
ated with more aggressive HCC phenotypes, although
these findings were not statistically significant. One
possible reason for this is that the SMMC-7721 cell
line used for the amplification experiment had lower
natural CDCA5 expression than the HepG2 negative
controls, such that there was only a modest difference
in CDCA5 expression between the two groups. Fur-
ther experimentation may be helpful in confirming
these preliminary findings.

![Fig. 7](image_url) Tumorigenicity of HepG2 cells in nude mice. 2 Tumors with different expression levels of CDCA5 formed in nude mice

![Fig. 8](image_url) CDCA5 expression in tumors produced by different groups of cells in mice (DAB staining, hematoxylin counterstain, magnification: 200 x)
An inverse correlation between CDCA5 expression in HCC and survival was also observed. Specifically, there was a statistically significant 12.3% difference in disease-free survival at 5 years as well as a 16.2% difference in overall survival at 5 years between patients with high CDCA5 expression and patients with low CDCA5 expression ($n = 178$). These results are largely consistent with Shen et al.’s findings, which showed 5-year survival differences between the high and low expression groups of approximately 12% for disease-free survival and approximately 14% for overall survival [11]. Furthermore, CDCA5 expression was higher in tumor tissue than normal hepatic or peritumoral tissue by immunohistochemistry in all 178 samples. The close consistency of our results with those of previous studies supports the idea of a role for CDCA5 in HCC prognosis [7–9, 11].

This study also confirmed that the inhibition of CDCA5 expression in hepatoma cells decreased the rate of proliferation and increased the rate of apoptosis as determined by colony formation assays and flow cytometry, which was consistent with previous studies [11]. The results also support the putative role of CDCA5 in chromatid separation during the G2/M transition [5, 6]. The effect of CDCA5 knockdown on tumor proliferation has been demonstrated in other cancers; in studies of oral squamous cell carcinoma and lung carcinogenesis, it was found that CDCA5 functions as a critical gene in proliferation and progression and that in certain cases, targeting CDCA5 may be a useful therapeutic intervention [7, 8]. These findings were further confirmed using nude mouse tumorigenesis experiments. The negative control mice developed larger tumors at 30 days (0.89 ± 0.07 g) than the CDCA5 knockdown mice (0.66 ± 0.11 g). Tumorigenesis was also faster in negative control mice than in the CDCA5 knockdown mice, with tumors being detected on the fifth day in the controls and on the sixth day in the knockdown group. Based on these studies and our results, CDCA5 is not only prognostic but may also be a potential treatment target in HCC.

The limitations of this study include the following. First, this was a pioneering single-center study on the impact of a novel biomarker on disease prognosis, with a total patient population of $n = 178$. Larger, multicenter studies may offer a greater degree of confidence supporting the role of CDCA5 in HCC. Second, the impact of CDCA5 expression in HCC as a screening or prognostic tool on the management of patients with HCC will require further study to determine if use of CDCA5 expression levels should become common practice. Further studies determining the utility of CDCA5 as a prognostic or predictive factor are needed. Last, although well beyond the scope of the present study, the all the molecular pathways in which CDCA5 plays a role have not been defined. Pathways in which CDCA5 has been implicated include the Wnt/β-catenin, RAS/RAF/ MAPK, and cyclin/cdk1 pathways [7, 9, 11, 18].

Conclusions

The present study found that CDCA5 overexpression in HCC was correlated with decreased survival, increased microvascular invasion, and increased tumor size in a real patient population. The effects of CDCA5 suppression observed in vitro confirm that it plays an essential role in the dysregulation of cell division. In brief, CDCA5 is a promising novel prognostic factor for patients with hepatocellular carcinoma.

Abbreviations

- AFP: Alpha fetoprotein
- CDCA5: Cell-division cycle associated 5
- HBV-DNA: Hepatitis B virus DNA
- HCC: Hepatocellular Carcinoma
- MELD: Model-End-Stage liver disease
- PLT: Platelet

Acknowledgements

Not applicable.

Funding

This work was supported by the Foundation of the Innovation Seeding Project of the Science & Technology Department of Sichuan Province (2017062) and the Cooperative Project of Nanchong City with North Sichuan Medical College (NSWC20170461). The funding body has no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

The datasets used and/or analyzed in the current study are available from the corresponding author on reasonable request.

Authors’ contributions

All authors contributed to the study design as well as the collection and analysis of the data. YT, YP, and JH designed the research; JW, SQ, and YD performed the clinical and basic research; YH, CC, and JH wrote the paper; CC, HL, and YH performed the statistical analyses. All authors approved the final version of the manuscript.

Ethics approval and consent to participate

This retrospective study was approved by the ethics committee of Nanchong Central Hospital and was carried out in accordance with the 1975 Helsinki Declaration. Because of the anonymous nature of the data and the opt-out option disclosed on our institution’s homepage, the requirement for additional informed consent to participate in this study was deemed unnecessary.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1. Department of General Surgery, Nanchong Central Hospital, The second Clinical College of North Sichuan Medical College, Nanchong 637000, Sichuan, China
2. Department of Radiology, Affiliated Zhongshan Hospital of Dalian University, 116011, No. 6 of JieFang Road, Dalian, China
3. Department of Radiology, Wayne State University, Detroit, MI 48201, USA
4. Department of Hepatobiliary Surgery of the Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China
5. The Sino-Dutch Biomedical and Information Engineering School of Northeastern University, Shenyang, China

Note

sN o t e
References

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–26.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
3. Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. Journal of gastrointestinal oncology. 2017;8(2):256–65.
4. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14.
5. Borton MT, Rashid MS, Dreier MR, Taylor WR. Multiple levels of regulation of Sororin by Cdk1 and Aurora B. J Cell Biochem. 2016;117(2):351–60.
6. Schmitz J, Watrin E, Lenart P, Mechtler K, Peters JM. Sororin is required for stable binding of cohesin to chromatins and for sister chromatid cohesion in interphase. Current biology : CB. 2007;17(7):630–4.
7. Nguyen MH, Koinuma J, Ueda K, Ito T, Tsuchiya E, Nakamura Y, et al. Phosphorylation and activation of cell division cycle associated 5 by mitogen-activated protein kinase play a crucial role in human lung carcinogenesis. Cancer Res. 2010;70(13):5337–47.
8. Tokuizen N, Nakashiro K, Tanaka H, Iwamoto K, Hamakawa H. Therapeutic potential of targeting cell division cycle associated 5 for oral squamous cell carcinoma. Oncotarget. 2016;7(3):2343–53.
9. Chang IW, Lin VC, He HL, Hsu CT, Li CC, Wu WJ, et al. CDCAS overexpression is an indicator of poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder. Am J Transl Res. 2015;7(4):710–22.
10. IBM Corp. Released 2013. IBM SPSS Statistics for Windows VA, NY: IBM Corp.
11. Shen Z, Yu X, Zheng Y, Lai X, Li J, Hong Y, et al. CDCAS regulates proliferation in hepatocellular carcinoma and has potential as a negative prognostic marker. OncoTargets and therapy. 2013;7(1):325–39.
12. Rodriguez-Peralvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20(1):325–39.
13. Lauwers GY, Terris B, Balis UJ, Batts KP, Regimbeau JM, Chang Y, et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol. 2000;24(1):25–34.
14. Cheng Z, Yang P, Lei Z, Zhang B, Si A, Yan Z, et al. Nomograms for prediction of long-term survival in elderly patients after partial hepatectomy for hepatocellular carcinoma. Surgery. 2017;162(6):1231–40.
15. Mazzaffero V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. The Lancet Oncology. 2009;10(1):35–43.
16. Mazzaffero V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9.
17. Kluger MO, Salceda JA, Laurent A, Tayar C, Duvoux C, Decaens T, et al. Liver resection for hepatocellular carcinoma in 313 Western patients: tumor biology and underlying liver rather than tumor size drive prognosis. J Hepatol. 2015;62(5):1131–40.
18. Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol. 2012;56(2):267–75.